Michael Pearson, chairman and CEO of Valeant Pharmaceuticals, discusses his company's $5.7-billion bid for U.S. drugmaker Cephalon, Inc.

Try Our New Player
tvnportal
1.6K
783 views
  • About
  • Export
  • Add to
Shares in pharmaceutical company Cephalon soared 28 per cent Wednesday after rival Mississauga-based Valeant Pharmaceuticals International made a $73 per share takeover offer. Powered by www.newslook.com Producer : CBC

0 comments